Population-Level Genetic Screening: Principles, Disorders, and Test Accuracy

Population-Level Genetic Screening

Overview of Population Screening in Genetics

Population-level genetic screening involves testing individuals in a population, often before symptoms arise, to identify carriers or those at risk for certain genetic disorders. This approach is commonly used in preconception, prenatal, and newborn settings, and aims to improve health outcomes by enabling early interventions.

• Carrier Screening: Identifies individuals who carry mutations for recessive disorders, allowing informed reproductive decisions.

• Newborn Screening: Detects genetic conditions early in life to enable prompt treatment.

• Interventions: Screening is prioritized for conditions where early intervention or treatment is possible.

CDC Tier One Genetic Disorders

The Centers for Disease Control and Prevention (CDC) has identified three 'tier one' genetic disorders for population screening, based on their impact and potential for intervention.

• Hereditary Breast and Ovarian Cancer (BRCA1 and BRCA2):

  • Variants in BRCA1 and BRCA2 genes increase risk for breast, ovarian, pancreatic, and prostate cancers.

  • Early detection allows for preventive measures such as early mammograms.

• Lynch Syndrome:

  • Caused by mutations in genes such as MSH6, MLH1, etc.

  • Predisposes to colon cancer, endometrial cancer, and others.

  • Early screening (e.g., colonoscopy) can significantly reduce morbidity.

• Familial Hypercholesterolemia:

  • Genetic disorder causing extremely high cholesterol levels, often manifesting in childhood.

  • Requires multifaceted treatment beyond lifestyle changes.

ACMG Secondary Findings and Whole Exome/Genome Sequencing

The American College of Medical Genetics and Genomics (ACMG) recommends reporting certain 'secondary findings' when performing broad genetic tests such as whole exome or genome sequencing. These findings are unrelated to the primary reason for testing but may have significant health implications.

• Whole Exome Sequencing: Analyzes the protein-coding regions (exons) of nearly all 20,000 genes.

• ACMG List: Initially 56 genes, expanded to 97 as of 2023, including genes related to cancer, cardiac conditions, and other actionable disorders.

• Secondary Findings: Pathogenic mutations in these genes are reported to patients, even if unrelated to their presenting symptoms.

• Whole Genome Sequencing: Extends analysis beyond exons to include non-coding regions.

Additional info: Secondary findings are often adult-onset conditions, and patients may choose whether to receive this information.

Genetic Test Accuracy and Interpretation

Key Concepts in Test Performance

Understanding the accuracy of genetic tests is crucial, especially in population screening where the prevalence of disorders is low. The main parameters are:

• Sensitivity: The proportion of true positives correctly identified by the test.

• False Positive Rate: The proportion of individuals without the condition who test positive.

• Prevalence: The frequency of the disorder in the population.

• Positive Predictive Value (PPV): The probability that a person who tests positive actually has the disorder.

Bayesian Approach to Test Interpretation

Bayesian reasoning is used to calculate the probability that a positive test result reflects true disease, considering test sensitivity, false positive rate, and disease prevalence.

• Example Calculation: For a rare disorder (1 in 1000 prevalence), a test with 99% sensitivity and 5% false positive rate yields a PPV of only 2%.

• Impact of Prevalence: Higher prevalence increases PPV; for 1 in 100 prevalence, PPV rises to 17%.

• Impact of False Positive Rate: Lowering the false positive rate (e.g., to 0.5%) dramatically increases PPV (up to 67% for 1 in 100 prevalence).

• Clinical Context: When testing individuals with high suspicion (e.g., 50% prior probability), PPV can exceed 99%.

Bayesian Formula for Positive Predictive Value

The probability that a positive test result is a true positive can be calculated as:

$\text{PPV} = \frac{\text{Sensitivity} \times \text{Prevalence}}{\text{Sensitivity} \times \text{Prevalence} + \text{False Positive Rate} \times (1 - \text{Prevalence})}$

Comparison of Test Scenarios

The following table summarizes how prevalence and false positive rate affect the likelihood that a positive test result is a true positive:

Prevalence	Sensitivity	False Positive Rate	Positive Predictive Value (PPV)
1 in 1000	99%	5%	2%
1 in 100	99%	5%	17%
1 in 100	99%	0.5%	67%
1 in 1000	99%	0.5%	17%
50% (clinical suspicion)	99%	0.5%	>99%

Additional info: Table values are based on example calculations provided in the notes.

Clinical vs. Population-Based Genetic Testing

Screening vs. Diagnostic Testing

Population-based screening is valuable for identifying individuals at increased risk, but it is not diagnostic. Diagnostic testing is reserved for individuals with symptoms or strong family history, where the likelihood of disease is higher and test results are more reliable.

• Population Screening: Identifies at-risk individuals for further evaluation.

• Diagnostic Testing: Confirms disease in symptomatic or high-risk individuals.

• Direct-to-Consumer Testing: Often lacks clinical context, reducing the predictive value of results.

Key Point: The value of genetic testing is greatest when there is clinical suspicion or relevant family history.

Implications for Practice

• Population screening can improve health outcomes but must be interpreted with caution.

• Patients should be informed about the limitations and predictive value of screening tests.

• Clinical decision-making should consider both test accuracy and individual risk factors.